30 closest matches · ranked by relevance
Primary Myelofibrosis (MF) · Post-Polycythemia Vera (PV) MF · Post-Essential Thrombocythemia (ET) MF
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 — 38 Participants — p=0.0007
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Primary Myelofibrosis (PMF) · Post Polycythaemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary: Percentage of Participants With Treatment Success — 50 Percentage of participants
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants
Polycythemia Vera
Primary: Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study — 3; 3; 3; 3 Participants
Myelofibrosis
Primary: Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score — 0; 16.7; 6.7; 13.3…
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post- Essential Thrombocythemia Myelofibrosis
Primary: Spleen Volume Reduction Response (≥ 35%) — 0; 2; 2; 0 Participants
Myelofibrosis · Polycythemia Vera · Thrombocytosis
Primary: Number of Participants With Adverse Events (AEs) — 30; 35; 47; 5 participants
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) Myelofibrosis · Postessential Thrombocythemia (Post-ET) Myelofibrosis
Primary: Transfusion Independence Response by Week 24 — 34.1 percentage of subjects
Polycythemia Vera (PV)
Primary: Proportion of Subjects Who Achieved Durable Phlebotomy-free Complete Hematological Response (CHR) at Month 12 — 8 Participants
Myeloproliferative Diseases
Primary: Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response — 2; 12; 2; 1 Participants
High Risk Polycythemia Vera · High Risk Essential Thrombocythemia
Primary: Number of Participants With Complete Remission (CR) — 17; 19; 12; 13 Participants
Myelofibrosis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years — 2153; 830 Participants
Myelofibrosis
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event — 0; 0; 0; 0 Participants
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Primary: Splenic Response Rate at Week 24 — 7; 3; 97; 49 Participants — p=0.90
Myeloproliferative Neoplasms
Primary: Number of Participants With Hematological Response, as Measured by Any One or More of the Following Response Assessments: IWG-MDS and IWG-MF Criteria as Accurate and…
Polycythemia Vera
Primary: Percentage of Patients With Overall Haematological Response at Week 12. — 54.5; 50.0; 45.5; 50.0 percentage of particpants
Myeloproliferative Disorders
Primary: Number of Patients With Complete Response (CR) or Partial Response (PR) — 3; 3; 14; 23 Participants
Polycythemia Vera
Primary: Number of Participants With Adverse Events - All Grades — 143; 26 Participants
Primary Myelofibrosis · Post-Polycythemia Vera · Myelofibrosis
Primary: Spleen Volume Response Rate (RR) — 35.8; 6.0 Percentage of Participants — p=<0.0001
Myelofibrosis With Myeloid Metaplasia · Myeloid Metaplasia · Myelofibrosis
Primary: Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment — 55.0; 23.5; 21.1; 47.6 percentage of participants — p=0.092
Primary Myelofibrosis · Anemia
Primary: The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period — 3; 2; 2; 10 Participants
Myelofibrosis
Primary: Efficacy of CC-5013 in Myelofibrosis — 7; 9; 12; 9 Participants
Myelofibrosis
Primary: Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16 — 78.0 Percentage of participants
Primary Myelofibrosis · MPN-associated Myelofibrosis
Primary: Percentage of Participants Who Achieved RBC-Transfusion Independence — 17.3; 16.7 percentage of participants — p=1.000
Myelofibrosis
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 — 28.5; 0 Percentage of Participants — p=<0.0001
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Mean Percentage Change From Baseline in Spleen Volume at Week 24 — -14.9 Percentage change